This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

Biogen agrees to acquire Reata in $7.3 billion deal

( July 28, 2023, 22:31 GMT | Official Statement) -- MLex Summary: Biogen has agreed to acquire Reata Pharmaceuticals in a deal worth around $7.3 billion. Biogen is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in treatments for neurological diseases. Reata is the maker of the only FDA-approved treatment for Friedreich's ataxia, a genetic disease that affects the nervous system. Both companies are traded on the Nasdaq. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections